Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation

Journal of Clinical Investigation

Volumn 118, Issue 8, 2008, Pages 2747-2757

  Sassi, Yassine ^a   Lipskaia, Larissa ^a   Vandecasteele, Grégoire ^b   Nikolaev, Viacheslav O ^c   Hatem, Stéphane N ^a   Aubart, Fleur Cohen ^a   Russel, Frans G ^d   Mougenot, Nathalie ^a   Vrignaud, Cédric ^e   Lechat, Philippe ^a,e   Lompré, Anne Marie ^a   Hulot, Jean Sébastien ^a,e  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIC GMP; MULTIDRUG RESISTANCE PROTEIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY INJURY; CELL ISOLATION; CELL PROLIFERATION; CORONARY ARTERY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTIMA; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

EID: 48749083091     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI35067     Document Type: Article

References (57)

1. Bos, J.L. 2006. Epac proteins: multi-purpose cAMP targets. Trends Biochem. Sci. 31:680-686.
2. Kaupp, U.B., and Seifert, R. 2002. Cyclic nucleotide-gated ion channels. Physiol. Rev. 82:769-824.
3. Rybalkin, S.D., Yan, C., Bornfeldt, K.E., and Beavo, J.A. 2003. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ. Res. 93:280-291.
4. Fischmeister, R., et al. 2006. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ. Res. 99:816-828.
5. Houslay, M.D., Baillie, G.S., and Maurice, D.H. 2007. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ. Res. 100:950-966.
6. Takimoto, E., et al. 2005. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. 11:214-222.
7. Osinski, M.T., Rauch, B.H., and Schror, K. 2001. Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol. Pharmacol. 59:1044-1050.
8. Houslay, M.D., Schafer, P., and Zhang, K.Y. 2005. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov. Today. 10:1503-1519.
9. Hamet, P., Pang, S.C., and Tremblay, J. 1989. Atrial natriuretic factor-induced egression of cyclic guanosine 3′:5′-monophosphate in cultured vascular smooth muscle and endothelial cells. J. Biol. Chem. 264:12364-12369.
10. Kapoor, C.L., and Krishna, G. 1977. Hormone-induced cyclic guanosine monophosphate secretion from guinea pig pancreatic lobules. Science. 196:1003-1005.
11. Sampath, J., et al. 2002. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 4:E14.
12. Borst, P., de Wolf, C., and van de Wetering, K. 2007. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 453:661-673.
13. Ritter, C.A., et al. 2005. Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab. Rev. 37:253-278.
14. Dazert, P., et al. 2003. Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. Am. J. Pathol. 163:1567-1577.
15. Mitani, A., Nakahara, T., Sakamoto, K., and Ishii, K. 2003. Expression of multidrug resistance protein 4 and 5 in the porcine coronary and pulmonary arteries. Eur. J. Pharmacol. 466:223-224.
16. Nies, A.T., Spring, H., Thon, W.F., Keppler, D., and Jedlitschky, G. 2002. Immunolocalization of multidrug resistance protein 5 in the human genitourinary system. J. Urol. 167:2271-2275.
17. Wielinga, P.R., et al. 2002. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol. Pharmacol. 62:1321-1331.
18. Nikolaev, V.O., Bunemann, M., Hein, L., Hannawacker, A., and Lohse, M.J. 2004. Novel single chain cAMP sensors for receptor-induced signal propagation. J. Biol. Chem. 279:37215-37218.
19. Klemm, D.J., et al. 2001. cAMP response element-binding protein content is a molecular determinant of smooth muscle cell proliferation and migration. J. Biol. Chem. 276:46132-46141.
20. Deeley, R.G., Westlake, C., and Cole, S.P. 2006. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 86:849-899.
21. Van Aubel, R.A., Smeets, P.H., van den Heuvel, J.J., and Russel, F.G. 2005. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am. J. Physiol. Renal Physiol. 288:F327-F333.
22. Chen, Z.S., Lee, K., and Kruh, G.D. 2001. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J. Biol. Chem. 276:33747-33754.
23. van Aubel, R.A., Smeets, P.H., Peters, J.G., Bindels, R.J., and Russel, F.G. 2002. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 13:595-603.
24. Wielinga, P.R., et al. 2003. Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J. Biol. Chem. 278:17664-17671.
25. Li, C., et al. 2007. Spatiotemporal Coupling of cAMP Transporter to CFTR Chloride Channel Function in the Gut Epithelia. Cell. 131:940-951.
26. Reid, G., et al. 2003. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol. Pharmacol. 63:1094-1103.
27. Schuetz, J.D., et al. 1999. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5:1048-1051.
28. Imaoka, T., et al. 2007. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol. Pharmacol. 71:619-627.
29. Jedlitschky, G., et al. 2004. The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood. 104:3603-3610.
30. Dodge-Kafka, K.L., et al. 2005. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature. 437:574-578.
31. Nagel, D.J., et al. 2006. Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ. Res. 98:777-784.
32. Ostrom, R.S., et al. 2002. Localization of adenylyl cyclase isoforms and G protein-coupled receptors in vascular smooth muscle cells: expression in caveolin-rich and noncaveolin domains. Mol. Pharmacol. 62:983-992.
33. Linder, A.E., McCluskey, L.P., Cole, K.R., 3rd, Lanning, K.M., and Webb, R.C. 2005. Dynamic association of nitric oxide downstream signaling molecules with endothelial caveolin-1 in rat aorta. J. Pharmacol. Exp. Ther. 314:9-15.
34. Indolfi, C., et al. 1997. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat. Med. 3:775-779.
35. Assender, J.W., Southgate, K.M., Hallett, M.B., and Newby, A.C. 1992. Inhibition of proliferation, but not of Ca2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth-muscle cells. Biochem. J. 288:527-532.
36. Southgate, K., and Newby, A.C. 1990. Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. Atherosclerosis. 82:113-123.
37. Sinnaeve, P., et al. 2002. Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis. Circulation. 105:2911-2916.
38. Cornwell, T.L., Arnold, E., Boerth, N.J., and Lincoln, T.M. 1994. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am. J. Physiol. 267:C1405-C1413.
39. Wu, Y.J., Bond, M., Sala-Newby, G.B., and Newby, A.C. 2006. Altered S-phase kinase-associated protein-2 levels are a major mediator of cyclic nucleotide-induced inhibition of vascular smooth muscle cell proliferation. Circ. Res. 98:1141-1150.
40. Aizawa, T., et al. 2003. Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ. Res. 93:406-413.
41. Gratton, J.P., Bernatchez, P., and Sessa, W.C. 2004. Caveolae and caveolins in the cardiovascular system. Circ. Res. 94:1408-1417.
42. Russel, F.G., Masereeuw, R., and van Aubel, R.A. 2002. Molecular aspects of renal anionic drug transport. Annu. Rev. Physiol. 64:563-594.
43. Maher, J.M., et al. 2007. Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology. 46:1597-1610.
44. Tardif, J.C. 2003. Clinical results with AGI-1067: a novel antioxidant vascular protectant. Am. J. Cardiol. 91:41A-49A.
45. Kamiya, K., et al. 2007. Phosphorylation of the cyclic AMP response element binding protein mediates transforming growth factor beta-induced downregulation of cyclin A in vascular smooth muscle cells. Mol. Cell. Biol. 27:3489-3498.
46. Ichiki, T., et al. 2003. Cyclic AMP response element-binding protein mediates reactive oxygen species-induced c-fos expression. Hypertension. 42:177-183.
47. Watson, P.A., Nesterova, A., Burant, C.F., Klemm, D.J., and Reusch, J.E. 2001. Diabetes-related changes in cAMP response element-binding protein content enhance smooth muscle cell proliferation and migration. J. Biol. Chem. 276:46142-46150.
48. Pulver, R.A., Rose-Curtis, P., Roe, M.W., Wellman, G.C., and Lounsbury, K.M. 2004. Store-operated Ca2+ entry activates the CREB transcription factor in vascular smooth muscle. Circ. Res. 94:1351-1358.
49. Lipskaia, L., et al. 2003. Phosphatidylinositol 3-kinase and calcium-activated transcription pathways are required for VLDL-induced smooth muscle cell proliferation. Circ. Res. 92:1115-1122.
50. Guo, Y., et al. 2003. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl) adenine. J. Biol. Chem. 278:29509-29514.
51. Dzau, V.J., Braun-Dullaeus, R.C., and Sedding, D.G. 2002. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 8:1249-1256.
52. Novak, K. 1998. Cardiovascular disease increasing in developing countries. Nat. Med. 4:989-990.
53. Humbert, M., Sitbon, O., and Simonneau, G. 2004. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 351:1425-1436.
54. Leggas, M., et al. 2004. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol. Cell. Biol. 24:7612-7621.
55. Lum, H., et al. 1999. Expression of PKA inhibitor (PKI) gene abolishes cAMP-mediated protection to endothelial barrier dysfunction. Am. J. Physiol. 277:C580-C588.
56. Lipskaia, L., et al. 2005. Sarco/endoplasmic reticulum Ca2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ. Res. 97:488-495.
57. Vallot, O., et al. 2000. Intracellular Ca(2+) handling in vascular smooth muscle cells is affected by proliferation. Arterioscler. Thromb. Vasc. Biol. 20:1225-1235.